Novavax (NVAX)
(Delayed Data from NSDQ)
$11.99 USD
+0.03 (0.25%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $11.96 -0.03 (-0.25%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.99 USD
+0.03 (0.25%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $11.96 -0.03 (-0.25%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Zacks News
A Guide to Small-Cap Value ETF Investing
by Sanghamitra Saha
The U.S. small-cap index the Russell 2000 has outperformed its bigger peer equity gauges by wide margin this year.
A Guide to Small-Cap Value ETF Investing
by Sanghamitra Saha
The U.S. small-cap index the Russell 2000 has outperformed its bigger peer equity gauges by wide margin this year.
Top-Performing ETF Areas of Last Week
by Sanghamitra Saha
The passage of the $1.9 trillion COVID-19 relief bill and tame inflation data boosted the markets last week.
6 Top Leveraged ETF Areas of Last Week
by Sanghamitra Saha
The S&P 500, the Dow Jones, the Nasdaq Composite and the small-cap Russell 2000 were all on an uptrend last week.
Novavax's (NVAX) COVID-19 Vaccine Shows Final Efficacy of 96.4%
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, proves to be 96.4% effective in final analysis in the phase III study in the United Kingdom. Shares up.
Company News for Mar 15, 2021
by Zacks Equity Research
Companies in the news are: CNTY, DS, EBON, NVAX
Novavax ETFs to Shine Bright on Positive Vaccine Update
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development and distribution amid the pandemic.
5 Stocks to Watch Amid Continued Expansion in the Biotech Industry
by Kaustav Ghosh
The biotech industry seems poised for further growth due to factors like advancements in drug research and faster regulatory process, making it wise to look at names like AbbVie (ABBV) and Novavax (NVAX)
Vaccine Miracles: Does JNJ Kill the Profit Path for MRNA and NVAX?
by Kevin Cook
New vaccine entrant gets approval before Novavax, while herd immunity ideas put sales in doubt.
Haverty Furniture, Noodles & Co, Novavax and Zoom Video highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Haverty Furniture, Noodles & Co, Novavax and Zoom Video highlighted as Zacks Bull and Bear of the Day
Novavax (NVAX) Loss Widens in Q4, Revenues Top Estimates
by Zacks Equity Research
Novavax's (NVAX) fourth-quarter 2020 loss is wider than estimates. Sales beat the same.
Markets Up Big Monday; Zoom (ZM) Beats, Novavax (NVAX) Misses Q4
by Mark Vickery
The Dow rose 1.95% on the day, +603 points; the S&P 500 gained 2.38%; the Nasdaq rose 3%, nearly 400 points; and the small-cap Russell 2000 took the cake, +3.37%.
Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q4
by Zacks Equity Research
Endo's (ENDP) earnings and sales beat estimates in the fourth quarter.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed the most recent trading day at $243.23, moving -0.76% from the previous trading session.
Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
During Novavax's (NVAX) upcoming fourth-quarter earnings call, investor focus will be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.
Earnings Preview: Novavax (NVAX) Q4 Earnings Expected to Decline
by Zacks Equity Research
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hedge Fund Diaries: Who Was Buying Your Stocks?
by Kevin Cook
SEC 13Fs reveal trades from months ago, but also patterns of long-term bullish behavior.
Are Stocks Too Hot to Buy?
by Tracey Ryniec
Lots of investors chased the big gains in the WSB/Reddit trades, but those stocks aren't the only ones that are soaring. How do you keep your cool in this red-hot market?
Zacks Market Edge Highlights: GameStop, AMC Entertainment, Chipotle, Novavax and NVIDIA
by Zacks Equity Research
Zacks Market Edge Highlights: GameStop, AMC Entertainment, Chipotle, Novavax and NVIDIA
Biotech Bonanza: COVID Launches Science at Warp Speed
by Kevin Cook
From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.
Biotech Stock Roundup: AMGN, VRTX Q4 Results, SAVA's Encouraging Drug Data & More
by Zacks Equity Research
Earnings of leading biotechs like Amgen (AMGN) and Vertex (VRTX) and vaccine updates from Novavax (NVAX) were some of the highlights of the biotech sector last week.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $264.41 in the latest trading session, marking a -1.45% move from the prior day.
6 ETFs You May Love to Buy for February
by Sanghamitra Saha
February is not known for good stock returns. However, this year could be different as global economies and corporates will strive hard to register a fast rebound from the COVID-19 slump.
Top-Performing ETFs of Last Week
by Sanghamitra Saha
Simple profit-booking and some warnings from the too-big-to-fail companies probably led to crash in Wall Street last week.
Novavax (NVAX) ETFs to Rise on Impressive Coronavirus Vaccine Update
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.